Recent regional cases of hantavirus infection have re‑raised global public health vigilance against this zoonotic pathogen. Sporadic cases have been reported in parts of Europe, Asia and North America in the first half of 2026, reminding medical authorities of the potential risks of seasonal outbreaks caused by rodent‑borne viruses. Hantavirus has a high mortality rate, and early diagnosis is critical for effective clinical intervention and infection control.
Traditional laboratory‑based nucleic acid testing requires professional laboratories and long detection cycles, which cannot fully meet on‑site screening needs in grassroots clinics, field monitoring and emergency scenarios. Against this background, the IVD industry is accelerating the upgrading of hantavirus rapid detection products. Colloidal gold‑based IgM/IgG antibody rapid test kits, which feature fast operation, intuitive results and no complex equipment requirements, have become mainstream diagnostic tools for hantavirus point‑of‑care testing.
Regulatory authorities in multiple countries have optimized approval channels for hantavirus detection reagents, promoting the market access of high‑quality IVD products. Market analysts predict that the global hantavirus rapid test market will maintain steady growth in the next 3‑5 years, driven by public health prevention requirements and increasing global health awareness.
As a professional supplier of infectious disease diagnostic reagents, our company provides high‑precision hantavirus IgM rapid test kits (colloidal gold method), strictly complying with international quality standards, to support global early warning and diagnosis of hantavirus infection.
コンタクトパーソン: Mr. Steven
電話番号: +8618600464506
Japanese
